Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

5.040 +0.460 (+10.04%)
Official Closing Price Updated: 8:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 243,800
Open 4.530
Bid (Size) 5.010 (1)
Ask (Size) 5.040 (2)
Prev. Close 4.580
Today's Range 4.500 - 5.050
52wk Range 4.000 - 14.70
Shares Outstanding 21,331,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer
Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access. 
Via Benzinga

Performance

YTD
-49.70%
-49.70%
1 Month
+10.04%
+10.04%
3 Month
-22.82%
-22.82%
6 Month
-34.88%
-34.88%
1 Year
-55.28%
-55.28%

More News

Read More
(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest
Via Benzinga
Actinium Shares Are Trading Higher After Positive Data From Acute Myeloid Leukemia Trial
Via Benzinga
With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
Via Benzinga
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
Via Investor's Business Daily
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
Via FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
What's Going On With Actinium Pharmaceuticals Stock?
Via Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Actinium Pharmaceuticals’ Shares Stay Bullish Ahead Of Expected Topline Phase 3 Data Release In Q4 ($ATNM)
Via AB Newswire
Actinium Pharmaceuticals’ Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year’s End ($ATNM)
Via AB Newswire
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
Via Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
4 Analysts Have This to Say About Actinium Pharmaceuticals
Via Benzinga
Why Is Getty Images (GETY) Stock Up 33% Today?
Via InvestorPlace
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Via Benzinga
PERF Stock Soars 21% on First Trading Day
Via InvestorPlace
Actinium (ATNM) Stock Pops on Positive Trial Results
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Actinium Pharmaceuticals’ Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 Catalysts ($ATNM)
Via AB Newswire
Actinium Pharmaceuticals’ Investor Update Puts Clinical Milestones And Potential Catalysts In The Crosshairs ($ATNM)
Via AB Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.